Evidence map›Paper›PMID 31889117›Full record

ArticleScientific reports2019

Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network.

Ryohei Fukuma, Takufumi Yanagisawa, Manabu Kinoshita, Takashi Shinozaki, Hideyuki Arita, Atsushi Kawaguchi, Masamichi Takahashi, Yoshitaka Narita, Yuzo Terakawa, Naohiro Tsuyuguchi and 18 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Noninvasive Determination ofAJNR. American journal of neuroradiology · 2021
    Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Artificial intelligence in neuro-oncology: methodological bases, practical applications and ethical and regulatory issues.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. [Research Progress in Imaging Investigation of TERT Promoter Mutations in Gliomas].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024
    Review
  13. Review
  14. Article
  15. Review
  16. Machine Learning and Radiomics in Gliomas.Advances in experimental medicine and biology · 2024
    Review
  17. Prediction ofFrontiers in neurology · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 12 institutions in 1 country.

Ryohei FukumaDepartment of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Takufumi YanagisawaDepartment of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. tyanagisawa@nsurg.med.osaka-u.ac.jp.
Manabu KinoshitaDepartment of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. mail@manabukinoshita.com.
Takashi ShinozakiCenter for Information and Neural Networks, National Institute of Information and Communications Technology, 1-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Hideyuki AritaDepartment of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Atsushi KawaguchiEducation and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, 849-8501, Japan.
Masamichi TakahashiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Yuzo TerakawaKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Naohiro TsuyuguchiKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Yoshiko OkitaDepartment of Neurosurgery, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka, 541-8567, Japan.
Masahiro NonakaKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Shusuke MoriuchiKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Masatoshi TakagakiDepartment of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yasunori FujimotoDepartment of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Junya FukaiKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Shuichi IzumotoKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Kenichi IshibashiKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Yoshikazu NakajimaKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Tomoko ShofudaKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Daisuke KanematsuKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Ema YoshiokaKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Yoshinori KodamaKobe University Graduate School of Medicine, Department of Diagnostic Pathology, 7-5-1 Kusunoki-cho Chuo-ku, Kobe, 650-0017, Japan.
Masayuki ManoKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Kanji MoriKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Koichi IchimuraDivision of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Yonehiro KanemuraKansai Molecular Diagnosis Network for CNS Tumors, Osaka, 540-0006, Japan.
Haruhiko KishimaDepartment of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Osaka University · JPOsaka National Hospital · JPKindai University · JPOsaka City General Hospital · JPKansai Medical University · JPKansai Rosai Hospital · JPKobe University · JPKyoto Seika University · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPSaga University · JPSakai Municipal Hospital · JPWakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of genotypes is crucial for treatment of glioma. Here, we developed a method to predict tumor genotypes using a pretrained convolutional neural network (CNN) from magnetic resonance (MR) images and compared the accuracy to that of a diagnosis based on conventional radiomic features and patient age. Multisite preoperative MR images of 164 patients with grade II/III glioma were grouped by IDH and TERT promoter (pTERT) mutations as follows: (1) IDH wild type, (2) IDH and pTERT co-mutations, (3) IDH mutant and pTERT wild type. We applied a CNN (AlexNet) to four types of MR sequence and obtained the CNN texture features to classify the groups with a linear support vector machine. The classification was also performed using conventional radiomic features and/or patient age. Using all features, we succeeded in classifying patients with an accuracy of 63.1%, which was significantly higher than the accuracy obtained from using either the radiomic features or patient age alone. In particular, prediction of the pTERT mutation was significantly improved by the CNN texture features. In conclusion, the pretrained CNN texture features capture the information of IDH and TERT genotypes in grade II/III gliomas better than the conventional radiomic features.

Indexed as

Magnetic Resonance ImagingMutationNeural Networks, ComputerPromoter Regions, GeneticBiomarkers, TumorFemaleGliomaHumansImage Processing, Computer-AssistedIsocitrate DehydrogenaseMaleNeoplasm GradingNeoplasm StagingReproducibility of ResultsTelomeraseBiomarkers, TumorIsocitrate DehydrogenaseTelomeraseTERT protein, human

Identifiers

PMID31889117
PMCPMC6937237
OpenAlexW2997384822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.